LRP1 and atherosclerosis: Imatinib (also known as Gleevec) is a tyrosine kinase inhibitor with relative specificity for PDGF receptors, as well as c-kit and Abl, which was shown to block autophosphorylation of PDGFR-β and tyrosine phosphorylation of the LRP1 ICD (12), and to protect in mouse models of aneurysm (56, 57) and atherosclerosis (12).